| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Obinutuzumab |
| Brand | Gazyvaro® |
| Indication | In combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy. |
| Assessment Process | |
| Rapid review commissioned | 08/08/2014 |
| Rapid review completed | 11/09/2014 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 30/09/2014 |
| NCPE assessment completed | 02/04/2015 |
| NCPE assessment outcome | Reimbursement not recommended. |
December 2015
The HSE has approved reimbursement following confidential price negotiations.
